Helicobacter pylori

Current Opinion in Infectious Diseases

Volumn 16, Issue 5, 2003, Pages 445-451

  Moss, Steven F ^a   Sood, Shivani ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Disease associations; Gastric cancer; Helicobacter pylori; Pathogenesis

Indexed keywords

AMOXICILLIN; BACTERIAL ENZYME; BACTERIAL VACCINE; BISMUTH CITRATE; CLARITHROMYCIN; ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; METRONIDAZOLE; PROTON PUMP INHIBITOR; RECOMBINANT ENZYME; SULFORAPHANE; TETRACYCLINE; UREASE; VIRULENCE FACTOR;

BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EPIDEMIOLOGICAL DATA; ESOPHAGUS DISEASE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PARASITE INTERACTION; HUMAN; IMMUNIZATION; LYMPHOID TISSUE; LYMPHOMA; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH CARCINOMA; STOMACH EPITHELIUM; STOMACH MUCOSA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 0142107379     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200310000-00011     Document Type: Review

References (58)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175-1186. A comprehensive and up-to-date review of H. pylori infection and clinical consequences.
2. Falush D, Wirth T, Linz B, et al. Traces of human migrations in Helicobacter pylori populations. Science 2003; 299:1582-1585. This is a fascinating account of the evolution of modern man constructed by genetic analysis of one of his most long-standing symbionts - H. pylori.
3. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of • Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 2002; 359:931-935. This paper underlines the importance of aiming treatment and preventive strategies at an early age in children.
4. Brown LM, Thomas TL, Ma JL, et al. Helicobacter pylori infection in rural China: demographic, lifestyle and environmental factors. Int J Epidemiol 2002; 31:638-645.
5. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ 2002; 324:999-1002. This is a well-controlled trial from Glasgow (50% prevalence of H. pylori) providing evidence to support deferring endoscopy in favor of a 'test-and-treat' strategy for H. pylori for dyspeptic patients.
6. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22. This is arguably the definitive statement on the longstanding controversy on the relationship of H. pylori with NSAIDs. This meta-analysis establishes the clinically important negative implications of concurrent use of NSAIDs in H. pylori-infected persons - an important and common current problem.
7. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9-13.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-180. These are recommendations on H. pylori management for the treating physician, generally evidence-based, though some conclusions remain contentious, outside Europe in particular.
9. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003:CD002096. This is a comprehensive review establishing a small but statistically significant role of H. pylori as a culprit in some cases of non-ulcer dyspepsia.
10. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. 1st American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52:6735-6740.
11. El-Omar EMCM, Chow W-H, McColl KEL, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
12. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am J Med 2002; 112:141-143.
13. Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123:92-105.
14. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94:1680-1687. This is a retrospective analysis of the ssociation of specific H. pylori virulence factors (Cag A presence and Vac A type) with polymorphisms for interleukin-1 beta and for the interleukin-1 receptor antagonist in Portuguese chronic gastritis and cancer patients reveals enormous differences in the odds ratio for gastric cancer that are dependent on both host and bacterial genotypes.
15. Kim JJ, Tao H, Carloni E, et al. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002; 123:542-553.
16. Yu J, Leung WK, Go MY, et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut 2002; 51:480-484.
17. Maeda S, Yoshida H, Mitsuno Y, et al. Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori. Gut 2002; 50:771-778. This is a careful analysis of signal transduction pathways relating to apoptosis following H. pylori co-culture. H. pylori signals to activate apoptosis through the death receptor pathway and its downstream effectors, and through mitochondrial cytochrome C release. Simultaneously, H. pylori activates anti-apoptotic pathways through NFkB, demonstrating a dual-signaling pathway influencing cell death decisions.
18. Fischbach W, Goebeler-Kolve M, Starostik P, et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicofaacter pylori. Lancet 2002; 360:547-548. Watchful waiting may be appropriate if some MALT lymphoma remains after successful eradication of H. pylori. Bigger studies are awaited.
19. Mueller A, O'Rourke J, Grimm J, et al. Distinct gene expression profiles characterize the histopathological stages of disease in Helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Proc Natl Acad Sci USA 2003; 100:1292-1297. This is an elegant dissection of changes in gene expression during the development of gastric MALT lymphomas in mice following H. pylori infection.
20. Blaser M. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179:1523-1530.
21. Vakil NB. Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 Suppl 1:47-51.
22. Rajkumar SV, Kyle RA, Plevak MF, et al. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 119:706-708.
23. Singh RK, McMahon AD, Patel H, et al. Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 2002; 88:43-46.
24. Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002; 106:430-434.
25. Pietroiusti A, Diomedi M, Silvestrini M, et al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 2002; 106:580-584.
26. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123:1763-1769.
27. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002; 99:7610-7615.
28. Banerjee S, Medina-Fatimi A, Nichols R, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51:634-640.
29. Akhiani AA, Pappo J, Kabok Z, et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002; 169:6977-6984.
30. Bumann D, Holland P, Siejak F, et al. A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening. Infect Immun 2002; 70:6494-6498.
31. Lee A, O'Rourke J, De Ungria MC, et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112:1386-1397.
32. Guo BP, Mekalanos JJ. Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice. Proc Natl Acad Sci USA 2002; 99:8354-8359. Very young mice with immature immune systems can be readily infected with human H. pylori strains (unlike many adult strains of mice).
33. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003; 63:942-950. Further analysis of the only established mouse model of H. pylori-associated gastric cancer demonstrates that only male mice develop malignant tumors. This finding opens a new line of research into H. pylori-associated carinogenesis.
34. Hofreuter D, Haas R. Characterization of two cryptic Helicobacter pylori plasmids: a putative source for horizontal gene transfer and gene shuffling. J Bacteriol 2002; 184:2755-2766.
35. Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414-424. OipA, an outer membrane protein, is closely associated with virulence and increased inflammation. In this study, OipA status was more predictive of inflammation and disease than other known H. pylori virulence factors.
36. Mahdavi J, Sonden B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297:573-578. This study describes a new addition to the growing list of H. pylori adhesins.
37. Fujikawa A, Shirasaka D, Yamamoto S, et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 2003; 33:375-381. Surprisingly, the protein tyrosine phosphatase receptor type Z may be the cellular receptor for H. pylori's Vac A.
38. Schraw W, Li Y, McClain MS, et al. Association of Helicobacter pylori vacuolating toxin (VacA) with lipid rafts. J Biol Chem 2002; 277:34642-34650.
39. Chattopadhyay S, Datta S, Chowdhury A, et al. Virulence genes in Helicobacter pylori strains from West Bengal residents with overt H. pylori-associated disease and healthy volunteers. J Clin Microbiol 2002; 40:2622-2625.
40. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295:683-686. A further examination of the functions of Cag A inside gastric epithelial cells reveals that it interacts with and influences the activity of cellular SHP-2 - a phosphatase known to be involved in the growth response to hepatocyte growth factor. Is this the elusive link between Cag A and cancer?
41. Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A 2002; 99:14428-14433. This describes a possible explanation for the high gastric cancer incidence in east Asia. All Cag A proteins are not equal - east Asian strains have multiple repeat units within Cag A that increases binding to SHP-2.
42. Selbach M, Moese S, Hurwitz R, et al. The Helicobacter pylori CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. EMBO J 2003; 22:515-528.
43. Tsutsumi R, Higashi H, Higuchi M, et al. Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. J Biol Chem 2003; 278:3664-3670.
44. Mimuro H, Suzuki T, Tanaka J, et al. Grb2 is a key mediator of Helicobacter pylori CagA protein activities. Mol Cell 2002; 10:745-755.
45. Hirata Y, Maeda S, Mitsuno Y, et al. Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation. Gastroenterology 2002; 123:1962-1971.
46. Guillemin K, Salama NR, Tompkins LS, Falkow S. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proc Natl Acad Sci U S A 2002; 99:15136-15141. A whole genomic approach reveals patterns differentially regulated by specific genes within H. pylori's cag PAI.
47. Stingl K, Uhlemann EM, Schmid R, et al. Energetics of Helicobacter pylori and its implications for the mechanism of urease-dependent acid tolerance at pH 1. J Bacteriol 2002; 184:3053-3060.
48. Fan XJ, Gunasena H, Cheng Z, et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 2000; 165: 1918-1924.
49. Gobert AP, Mersey BD, Cheng Y, et al. Cutting edge: urease release by Helicobacter pylori stimulates macrophage inducible nitric oxide synthase. J Immunol 2002; 168:6002-6006.
50. Olson JW, Maier RJ. Molecular hydrogen as an energy source for Helicobacter pylori. Science 2002; 298:1788-1790. H. pylori has an inducible hydrogenase that utilizes gastric hydrogen as an energy source. This appears very important for gastric colonization.
51. O'Rourke EJ, Chevalier C, Pinto AV, et al. Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in Helicobacter pylori colonization. Proc Natl Acad Sci U S A 2003; 100:2789-2794.
52. Schilling CH, Covert MW, Famili I, et al. Genome-scale metabolic model of Helicobacter pylori 26695. J Bacteriol 2002; 184:4582-4593.
53. Chowers MY, Keller N, Bar-Meir S, Chowers Y. A defined human gastrin sequence stimulates the growth of Helicobacter pylori. FEMS Microbiol Lett 2002; 217:231-236. H. pylori stimulates gastrin release. Here is further evidence that gastrin also stimulates the growth of H. pylori.
54. Graham JE, Peek Jr RM, Krishna U, Cover TL. Global analysis of Helicobacter pylori gene expression in human gastric mucosa. Gastroenterology 2002; 123:1637-1648. Analysis of H. pylori's genes transcribed following contact with gastric epithelial cells may elucidate novel virulence genes and identify those that are essential for successful colonization in vivo.
55. Cover TL, Krishna US, Israel DA, Peek Jr RM. Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Cancer Res 2003; 63:951-957.
56. Shibayama K, Kamachi K, Nagata N, et al. A novel apoptosis-inducing protein from Helicobacter pylori. Mol Microbiol 2003; 47:443-451.
57. Bumann D, Aksu S, Wendland M, et al. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect Immun 2002; 70:3396-3403.
58. Kim N, Weeks DL, Shin JM, et al. Proteins released by Helicobacter pylori in vitro. J Bacteriol 2002; 184:6155-6162.